Compare Quanta Services Inc (PWR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Quanta Services Inc trades at $692.27 (market cap $105.40B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Quanta Services Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PWR | REGN | |
|---|---|---|
Market Cap | $105.40B | $76.40B |
Volume | 1,014,408 | 626,381 |
Sector | Industrials | Health |
52-Week High | $785.24 | $852.03 |
52-Week Low | $412.21 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $111.50B | $71.12B |
Dividend Yield | 0.06% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quanta Services (PWR) trades at $685.33, down 4.76% on the day, but maintains a bullish technical trend with strong analyst support. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, with net income reaching $1.03B. The company benefits from a record $53B backlog and positive earnings surprises, though valuation multiples like a P/E of 80.21 suggest premium pricing. Recent news highlights PWR's role in AI infrastructure and data center spending, driving investor optimism.
Outlook remains positive given strong earnings beats and sector tailwinds, but high valuation and execution risks from rapid expansion pose challenges. Analysts see 26.5% upside to a $802.08 consensus target, with no sell ratings. Risks include margin pressure and macroeconomic sensitivity, yet institutional bullishness and operational momentum support long-term growth potential.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
